Diabetes Mellitus (DM) represents a significant global health crisis, with over 550 million adults affected worldwide. This condition elevates blood glucose levels due to insulin dysregulation. This physiological change leads to severe complications such as cardiovascular diseases, retinopathy, and neuropathy. Current therapeutic approaches, including inhibitors of carbohy drate digesting enzymes, SGLT-2 inhibitors, and DPP-4 inhibitors, are effective but often are companied by adverse side effects. Consequently, the products derived from natural plants, have been emphasized for their potential antidiabetic properties. The current research focuses on in silico approaches towards the antidiabetic potential of bioactive compounds from Gymnema sylvestre (GS). The dry lab tools and techniques such as molecular docking, ADMET profiling, and PASS analysis have been applied to evaluate 54 natural compounds from GS. Our findings revealed that Alternoside 16, Alternoside 6, and Alternoside 7, along with Gymnemic acids (IV, XIV) and Gymnemosides (D, F), showed stronger binding affinities and low inhibition constants across multiple targets. To validate the stability, 2 of the docked molecules were evaluated using molecular dynamics simulations (MDS). This study explores the therapeutic potential of GS-derived compounds and provides a basis for future research into their clinical applications in diabetes management.